Sanofi has unveiled an investment of more than €600 million (~$707mn) in a new vaccine manufacturing facility at its existing site in Toronto, Canada. The investment in a new facility will provide additional antigen and filling capacity for Sanofi’s Fluzone High-Dose Quadrivalent influenza vaccine, helping to increase supply availability in Canada, the United States and Europe.   “As a leading vaccines company, we continuously look ahead to address the fast-growing demand for those influenza vac...